InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report published on Sunday. The firm issued a sell rating on the stock.

A number of other equities analysts have also commented on the company. Lake Street Capital assumed coverage on InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Performance

NSPR opened at $2.71 on Friday. The firm has a market cap of $70.69 million, a P/E ratio of -3.61 and a beta of 0.99. The business has a 50 day moving average price of $2.74 and a 200 day moving average price of $2.70. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.42.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the previous year, the company earned ($0.15) earnings per share. As a group, analysts anticipate that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.